Table 1 Classification based on the response to a biologic treatment for severe asthma.
From: Real-life cost-effectiveness of benralizumab in patients with severe asthma
Exacerbationsa | ACT | FEV1 | Systemic corticosteroids | |
|---|---|---|---|---|
No response | Identical or increased number | < 3-point increase | < 10% and 100 mL increase | < 50% decrease |
Partial response | < 50% reduction ≥ 2 severe exacerbations in 12 months | < 3-point increase Total score < 20 | > 10% and 100 mL increase FEV1 < 80% | > 50% dose decrease No OCS discontinuation |
Controlled asthma | ≤ 1 severe exacerbation in 12 months | Total score ≥ 20 | FEV1 < 80% | OCS discontinuation |
Complete response | No exacerbations in 12 months | Total score ≥ 20 | FEV1 ≥ 80% | OCS discontinuation |